









Markets
/
Stocks
/
nasdaq-cphi
/

China Pharma Holdings Inc

CPHI

0.694USD

+0.034+5.37%

Close 02/06, 16:00（ET）Quotes delayed by 15 min

3.48MMarket Cap

LossP/E TTM



China Pharma Holdings Inc

0.694

+0.034+5.37%

Overview Financials Analysis Company

TradingKey Stock Score

Overall Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment

Peer Comparison

Overview

Financials

Analysis

Company

TradingKey Stock Score

Overall Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment

Peer Comparison

TradingKey Stock Score of China Pharma Holdings Inc

Currency: USD Updated: 2026-02-06

Key Insights

China Pharma Holdings Inc's fundamentals are relatively stable, with an industry-leading ESG disclosure.and its growth potential is significant.Its valuation is considered fairly valued, ranking 123 out of 159 in the Pharmaceuticals industry.Institutional ownership is very high.In the medium term, the stock price is expected to trend down.Despite a very weak stock market performance over the past month, the company shows strong fundamentals.The stock price is trading sideways between the support and resistance levels, making it suitable for range-bound swing trading.

China Pharma Holdings Inc's Score

Industry at a Glance

Industry Ranking

123 / 159

Overall Ranking

445 / 4521

Industry

Pharmaceuticals

Support & Resistance

Relevant data have not been disclosed by the company yet.

Score Analysis

Current score

Previous score

Media Coverage

Last 24 hours

Coverage Level

Very Low

Very High

Neutral

China Pharma Holdings Inc Highlights

StrengthsRisks

China Pharma Holdings Inc is a company principally engaged in the development, manufacture and marketing of pharmaceutical products. The Company's products are for human use in connection, and with a variety of high-incidence and high-mortality diseases and medical conditions prevalent. The Company manufactures pharmaceutical products in the form of dry powder injectables, liquid injectables, tablets, capsules, and cephalosporin oral solutions. In addition, the Company is also engaged in the production of comprehensive healthcare products and protective products.

Growing

The company is in a growing phase, with the latest annual income totaling USD 4.53M.

High Profit Growth

The company's net income leads the industry, with the latest annual income totaling USD 4.53M.

Overvalued

The company’s latest PE is -0.68, at a high 3-year percentile range.

Held by James Simons

Star Investor James Simons holds 10.62K shares of this stock.

Analyst Rating

Based on 0 analysts

Current Rating

0.000

Target Price

0.00%

Upside Space

Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.

Financial Health

Currency: USD Updated: 2026-02-06

The current financial score of China Pharma Holdings Inc is 6.83, ranking 137 out of 159 in the Pharmaceuticals industry. Its financial status is weak, and its operating efficiency is high. Its latest quarterly revenue reached 756.22K, representing a year-over-year decrease of 31.26%, while its net profit experienced a year-over-year decrease of 41.72%.

Score

Industry at a Glance

Previous score

6.83

Change



Financials

5.00

Key Metrics

Cash and cash equivalents

Total assets

Total liabilities

Free cash flow

Relevant data have not been disclosed by the company yet.



Quality of Earnings

6.97

Key Metrics

Total revenue

Operating profit

Total assets

SG&A

Relevant data have not been disclosed by the company yet.



Operational Efficiency

10.00

Key Metrics

Cash flow from operating activities

Income after tax

Relevant data have not been disclosed by the company yet.



Growth Potential

4.96

Key Metrics

Cash flow from operating activities

Total revenue

Relevant data have not been disclosed by the company yet.



Shareholder Returns

7.19

Key Metrics

Free cash flow

Relevant data have not been disclosed by the company yet.

China Pharma Holdings Inc's Company Valuation

Currency: USD Updated: 2026-02-06

The current valuation score of China Pharma Holdings Inc is 8.60, ranking 12 out of 159 in the Pharmaceuticals industry. Its current P/E ratio is -0.68, which is -61.90% below the recent high of -0.26 and -2188.55% above the recent low of -15.47.

Score

Industry at a Glance

Previous score

8.60

Change

Valuation Dimensions

P/E

P/B

P/S

P/CF

Industry Ranking 123/159

Relevant data have not been disclosed by the company yet.

Earnings Forecast

Currency: USD Updated: 2026-02-06

No earnings forecast score is currently available for China Pharma Holdings Inc. The Pharmaceuticals industry's average is 7.85.

Score

Industry at a Glance

Previous score

0.00

Change

Support & Resistance

Relevant data have not been disclosed by the company yet.

No Data

Financial Forecasting

EPS

Revenue

Net Profit

EBIT

Relevant data have not been disclosed by the company yet.

Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.

Price Momentum

Currency: USD Updated: 2026-02-06

The current price momentum score of China Pharma Holdings Inc is 4.47, ranking 147 out of 159 in the Pharmaceuticals industry. Currently, the stock price is trading between the resistance level at 1.21 and the support level at 0.39, making it suitable for range-bound swing trading.

Score

Industry at a Glance

Previous score

4.80

Change

-0.33

Support & Resistance

Relevant data have not been disclosed by the company yet.

Indicators



The Indicators feature provides value and direction analysis for various instruments under a selection of technical indicators, together with a technical summary.

This feature includes nine of the commonly used technical indicators: MACD, RSI, KDJ, StochRSI, ATR, CCI, WR, TRIX and MA. You may also adjust the timeframe depending on your needs.

Please note that technical analysis is only part of investment reference, and there is no absolute standard for using numerical values to assess direction. The results are for reference only, and we are not responsible for the accuracy of the indicator calculations and summaries.

Indicators

Sell(4)

Neutral(0)

Buy(1)

Indicators

Value

Direction

MACD(12,26,9)

-0.113

Sell

RSI(14)

23.108

Sell

STOCH(KDJ)(9,3,3)

8.390

Oversold

ATR(14)

0.155

High Vlolatility

CCI(14)

-135.632

Sell

Williams %R

90.010

Oversold

TRIX(12,20)

-1.434

Sell

StochRSI(14)

80.773

Buy

Moving Average

Sell(6)

Neutral(0)

Buy(0)

Indicators

Value

Direction

MA5

0.772

Sell

MA10

1.005

Sell

MA20

1.136

Sell

MA50

1.345

Sell

MA100

1.557

Sell

MA200

1.656

Sell

Institutional Confidence

Currency: USD Updated: 2026-02-06

The current institutional shareholding score of China Pharma Holdings Inc is 3.00, ranking 93 out of 159 in the Pharmaceuticals industry. The latest institutional shareholding proportion is 2.51%, representing a quarter-over-quarter decrease of 35.05%. The largest institutional shareholder is James Simons, holding a total of 10.62K shares, representing 0.21% of shares outstanding, with 49.61% increase in holdings.

Score

Industry at a Glance

Previous score

3.00

Change

Institutional Shareholding

Relevant data have not been disclosed by the company yet.

Shareholder Activity

Name

Shares Held

Chg %

Yang (Yan)

450.00K

Zhan (Wenlong)

410.00K

Jianying (Cai)

400.00K

+300.00%

Lai (Kui)

400.00K

+300.00%

Lihua (Li)

400.00K

+300.00%

Li (Zhilin)

302.76K

+0.00%

Liu (Tao Chengdu)

300.00K

Citadel Advisors LLC

30.43K

+31.89%

Tsui (Heung Mei)

18.63K

+0.01%

Renaissance Technologies LLC

Star Investors

10.62K

Risk Assessment

Currency: USD Updated: 2026-02-06

The U.S. Dollar Index is currently in a neutral state, which has a neutral effect on the Pharmaceuticals domestic-focused industry. The Dollar Index (DXY) measures the value of the U.S. dollar against a basket of major currencies, including the euro, yen, pound sterling, Canadian dollar, Swedish krona, and Swiss franc. The current risk assessment score of China Pharma Holdings Inc is 2.42, ranking 129 out of 159 in the Pharmaceuticals industry. The company's beta value is 1.19. This indicates that the stock tends to outperform the index during upward trending markets but experiences larger declines during downward trending markets. with an industry-leading ESG disclosure.